Royalty Pharma (RPRX) Q2 2024 earnings summary

Executive summary

• Achieved 12% year-over-year growth in Portfolio Receipts to $608 million in Q2 2024, surpassing guidance, with Royalty Receipts up 11% driven by cystic fibrosis, Trelegy, Tremfya, and Evrysdi.

• Raised full-year 2024 guidance for Portfolio Receipts to $2.7–$2.775 billion and Royalty Receipts growth to 9–12%, reflecting strong performance and new investments.

• Deployed over $2 billion in capital, including six new royalty acquisitions such as Voranigo and expanded partnerships, with $905 million for Voranigo and $1 billion for additional Evrysdi royalties.

• Maintained leadership in the biopharma royalty market, executing 20 of 26 $500M+ transactions since IPO and holding royalties on 35+ commercial products and 16 development-stage candidates.

• Continued share repurchases, with $115 million repurchased YTD and a robust deal pipeline supporting long-term growth confidence.

Financial highlights

• Adjusted EBITDA for Q2 2024 was $574 million (94.3% margin), and Portfolio Cash Flow was $574 million, with net cash from operating activities up 8% to $658 million.

• Net income attributable to Royalty Pharma plc was $102 million for Q2 2024, down from $228 million in Q2 2023.

• Cash and cash equivalents stood at $1.8 billion as of June 30, 2024, with total debt at $7.8 billion.

• Issued $1.5 billion in senior unsecured notes at a 5.5% coupon, extending average debt duration to 13 years and maintaining a weighted-average cost of debt at 3.1%.

• Share repurchases totaled $84 million in Q2 and $115 million YTD, with $610.8 million remaining under the program.

Outlook and guidance

• Full-year 2024 Portfolio Receipts guidance raised to $2.7–$2.775 billion, with Royalty Receipts growth expected at 9–12%.

• Operating and professional costs projected at 8–9% of Portfolio Receipts; interest paid expected at ~$160 million for 2024.

• Milestones and other contractual receipts expected to decline from $600 million in 2023 to $30 million in 2024.

• No additional debt financing expected in 2024; 2025 interest paid projected at ~$260 million.

• Guidance excludes future transactions and assumes negligible FX impact.